SSC Faces Uphill Battle For Funds

WASHINGTON—In some places, April showers may indeed bring May flowers. But in this town the vegetation must compete with the lobbyists, who appear in droves each spring to plead for their favorite projects as part of.the annual federal budget process. This year, advocates of the superconducting supercollider (SSC) are hoping to avoid last year’s bitter harvest, when Congress refused to spend anything to begin preparing for construction and instead retained level funding—$

Written byJeffrey Mervis
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WASHINGTON—In some places, April showers may indeed bring May flowers. But in this town the vegetation must compete with the lobbyists, who appear in droves each spring to plead for their favorite projects as part of.the annual federal budget process.

This year, advocates of the superconducting supercollider (SSC) are hoping to avoid last year’s bitter harvest, when Congress refused to spend anything to begin preparing for construction and instead retained level funding—$98 million this year—for continued development of the 10,000 superconducting magnets and related research. That decision forced the Department of Energy to extend by two years the completion date for the $6 billion accelerator, to 1998. This year President Bush has requested $250 million, with $160 million for construction, but advocates are worried that history will repeat itself and the project will be further delayed.

To prevent that from happening, proponents are pushing to extend their base of support ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies